Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MDWD Stock Forecast 2026-2027
$14.18
Current Price
$182.24M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MDWD Price Targets
+153.9%
To High Target of $36.00
+118.6%
To Median Target of $31.00
+55.1%
To Low Target of $22.00
MDWD Price Momentum
+2.6%
1 Week Change
-14.4%
1 Month Change
-34.4%
1 Year Change
-23.2%
Year-to-Date Change
-35.8%
From 52W High of $22.09
+4.7%
From 52W Low of $13.54
📊 TOP ANALYST CALLS
Did MDWD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MediWound is one of their latest high-conviction picks.
Latest MDWD Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, MDWD has a bullish consensus with a median price target of $31.00 (ranging from $22.00 to $36.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $14.18, the median forecast implies a 118.6% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 153.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDWD Analyst Ratings
6
Buy
0
Hold
0
Sell
MDWD Price Target Range
Low
$22.00
Average
$31.00
High
$36.00
Current: $14.18
Latest MDWD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDWD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 28, 2026 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $32.00 |
| May 28, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $36.00 |
| Nov 21, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 28, 2025 | Craig-Hallum | Buy | Initiates | $N/A | |
| Jan 10, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 27, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 30, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 22, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 16, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 22, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 21, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 17, 2023 | Oppenheimer | Outperform | Maintains | $N/A | |
| Aug 17, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 31, 2023 | Oppenheimer | Outperform | Reiterates | $N/A | |
| May 31, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
MediWound Ltd. (MDWD) Competitors
The following stocks are similar to MediWound based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MediWound Ltd. (MDWD) Financial Data
MediWound Ltd. has a market capitalization of $182.24M with a P/E ratio of -6.8x. The company generates $14.48M in trailing twelve-month revenue with a -180.3% profit margin.
Revenue growth is -62.7% quarter-over-quarter, while maintaining an operating margin of -541.0% and return on equity of -71.8%.
Valuation Metrics
Market Cap
$182.24M
Enterprise Value
$146.03M
P/E Ratio
-6.8x
PEG Ratio
0.0x
Price/Sales
12.6x
Growth & Margins
Revenue Growth (YoY)
-62.7%
Gross Margin
+21.9%
Operating Margin
-541.0%
Net Margin
-180.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+24.5%
Current Ratio
2.4x
Debt/Equity
19.6x
ROE
-71.8%
ROA
-23.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MediWound Ltd. (MDWD) Business Model
About MediWound Ltd.
What They Do
Develops enzymatic therapeutics for tissue repair.
Business Model
MediWound Ltd. operates as an integrated biopharmaceutical company that develops, manufactures, and commercializes biologics targeting severe burns and chronic wounds. The company generates revenue primarily through the sale of its FDA-approved products, like NexoBrid, and its pipeline candidates, by forming strategic partnerships for global commercialization.
Additional Information
The company's lead product, NexoBrid, offers a non-surgical solution for burn treatment, focusing on preserving healthy tissue and reducing healing complications. MediWound has a cGMP-certified manufacturing facility in Israel and aims to expand its market presence through partnerships in major regions, including the U.S., Europe, and Japan.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
111
CEO
Country
Israel
IPO Year
2014
Website
www.mediwound.comMediWound Ltd. (MDWD) Latest News & Analysis
Latest News
MediWound Q1 Earnings Call Highlights
12 days ago
Quick Summary
MediWound (NASDAQ: MDWD) reported a wider Q1 loss and lower revenue year-over-year but reaffirmed its 2026 revenue outlook and progress on EscharEx and NexoBrid programs.
Why It Matters
MediWound's wider loss and lower revenue raise concerns about financial health, but reaffirming the 2026 outlook and progress on key programs may signal long-term growth potential.
Source: MarketBeat
Market Sentiment:
Negative
Quick Summary
MediWound Ltd. (MDWD) held its Q1 2026 earnings call, providing updates on financial performance and company developments. Further details can be found in the transcript.
Why It Matters
MediWound's Q1 2026 earnings reveal financial performance, growth prospects, and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
MediWound (MDWD) reported a quarterly loss of $0.23 per share, better than the estimated loss of $0.65, but worse than a loss of $0.07 per share from the previous year.
Why It Matters
MediWound's smaller-than-expected loss signals improved performance, potentially boosting investor confidence and affecting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
MediWound Ltd. announced progress in its Phase III VALUE trial for EscharEx® with interim results expected by Q1 2027. Q1 2026 revenue was $1.5M, reaffirming annual guidance of $24-26M.
Why It Matters
The Phase III trial progress and reaffirmed revenue guidance indicate potential for future growth, influencing investor sentiment and stock performance for MediWound Ltd.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MediWound Ltd. will report its Q1 2026 financial results on May 27 at 8:30 a.m. ET, with a conference call and webcast scheduled for the event.
Why It Matters
MediWound's upcoming financial results could impact stock performance, revealing insights into growth, revenue, and overall company health, influencing investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
1 month ago
Quick Summary
MediWound Ltd. (Nasdaq: MDWD) announced a peer-reviewed consensus supporting advanced debridement methods for chronic wounds, aligning with its product EscharEx® and reinforcing its market strategy.
Why It Matters
The consensus supports MediWound's approach, enhancing EscharEx®'s commercial potential in chronic wound care, which could lead to increased sales and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MDWD Stock
What is MediWound Ltd.'s (MDWD) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, MediWound Ltd. (MDWD) has a median price target of $31.00. The highest price target is $36.00 and the lowest is $22.00.
Is MDWD stock a good investment in 2026?
According to current analyst ratings, MDWD has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDWD stock?
Wall Street analysts predict MDWD stock could reach $31.00 in the next 12 months. This represents a 118.6% increase from the current price of $14.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MediWound Ltd.'s business model?
MediWound Ltd. operates as an integrated biopharmaceutical company that develops, manufactures, and commercializes biologics targeting severe burns and chronic wounds. The company generates revenue primarily through the sale of its FDA-approved products, like NexoBrid, and its pipeline candidates, by forming strategic partnerships for global commercialization.
What is the highest forecasted price for MDWD MediWound Ltd.?
The highest price target for MDWD is $36.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 153.9% increase from the current price of $14.18.
What is the lowest forecasted price for MDWD MediWound Ltd.?
The lowest price target for MDWD is $22.00 from at , which represents a 55.1% increase from the current price of $14.18.
What is the overall MDWD consensus from analysts for MediWound Ltd.?
The overall analyst consensus for MDWD is bullish. Out of 3 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $31.00.
How accurate are MDWD stock price projections?
Stock price projections, including those for MediWound Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 12:29 PM UTC